What is the difference between Section 361 and Section 351 tissue products?

Section 361 HCT/Ps are minimally manipulated human tissues intended for homologous structural use that do not require premarket FDA approval. Section 351 products involve more than minimal manipulation or non-homologous use, classifying them as biological drugs requiring clinical trials and formal BLA approval.

How can a practice manager verify if a tissue distributor is compliant?

A practice manager should request the distributor's state distribution license, the processing manufacturer's active FDA Establishment Registration (Form FDA 3356), lot-specific Certificates of Analysis confirming sterility and endotoxin clearance, and documentation of validated cold-chain transport.

What happens if a practice uses a tissue product deemed non-compliant by the FDA?

Using non-compliant HCT/Ps that fail Section 361 criteria can subject a practice to regulatory scrutiny, FDA warning letters, product seizures, patient liability claims, and severe disruption to practice operations.

Are exosomes considered FDA Section 361 tissue products?

No, the FDA has clarified that acellular isolation products, including isolated exosomes, do not meet the criteria for Section 361 human tissue products and are regulated as Section 351 drugs requiring an IND or premarket approval.

FDA Section 361 Tissue Product Compliance

FDA section 361 tissue product compliance for regenerative medicine distributors mandates that HCT/Ps meet 21 CFR Part 1271 criteria for minimal manipulation and homologous use without requiring premarket approval. Sourcing unapproved 351 biologics misbranded as 361 tissue products exposes clinical practices to severe regulatory enforcement, product seizures, and legal liability. This guide outlines essential due diligence workflows and documentation checks for evaluating biologics suppliers to ensure long-term practice compliance and chain-of-custody integrity.

Understanding FDA Section 361 for Human Tissue Products

The regulatory landscape for human cells, tissues, and cellular and tissue-based products (HCT/Ps) is governed by the Food and Drug Administration (FDA) under two primary pathways within the Public Health Service (PHS) Act: Section 361 and Section 351.

Section 361 HCT/Ps are regulated solely to prevent the introduction, transmission, or spread of communicable diseases. These products do not require premarket approval, Biologics License Applications (BLAs), or investigational new drug (IND) applications, provided they meet specific, narrow statutory criteria. When a distributor provides tissue products—such as amniotic membrane, umbilical cord tissue, or allograft matrix—under Section 361, both the distributor and the manufacturer must maintain strict adherence to 21 CFR Part 1271.

If a product fails to meet even one of the Section 361 criteria, the FDA reclassifies it as a Section 351 drug, device, or biological product. Section 351 products require extensive clinical trials and formal FDA approval prior to marketing. Medical practices using or purchasing non-compliant HCT/Ps inadvertently expose themselves to serious legal, operational, and ethical liabilities.

Core Criteria for Section 361 HCT/P Qualification

To qualify under Section 361, a tissue product and its distributing network must strictly satisfy four primary regulatory standards established under 21 CFR 1271.10(a):

1. Minimal Manipulation

For structural tissue, minimal manipulation means processing that does not alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement. For non-structural cellular tissue, minimal manipulation means processing that does not alter the relevant biological characteristics.

2. Homologous Use

Homologous use dictates that the cell or tissue performs the same basic function or functions in the recipient as in the donor. For example, using structural connective tissue to cover or protect a wound, or support structural defects, aligns with homologous use. Claiming that a structural tissue treats systemic conditions, metabolic disorders, or neurological diseases violates homologous use standards.

3. Non-Combined Status

The HCT/P must not be combined with another article, such as a drug or device, except for water, crystalloids, or a sterilizing, preserving, or storage agent that does not raise new clinical safety concerns.

4. Systemic Effect and Metabolic Dependence

The tissue must not have a systemic effect and must not depend upon the metabolic activity of living cells for its primary function, unless it is intended for autologous use, allogeneic use in first- or second-degree blood relatives, or reproductive use.

Distributor Compliance Checklist for Practice Managers

When evaluating a distributor for biologics, practice managers must look beyond marketing claims and verify official regulatory document packages. Use this checklist during your vendor qualification process:

FDA Registration and Listing Verification: Confirm that the manufacturer and tissue bank maintain active FDA registration via the FDA Establishment Registration Portal (21 CFR Part 1271 Subpart B).
Current Good Tissue Practice (cGTP) Documentation: Request proof that processing facilities adhere strictly to cGTP guidelines governing donor screening, serology testing, facility sanitation, and environmental controls.
State Tissue Bank Licensing: Ensure the distributor holds valid state-level tissue distributor or wholesaler licenses where required (such as Texas License #1002308).
Lot-Specific Certificates of Analysis (CoA): Verify that every shipment includes CoAs detailing sterility testing (USP <71>), endotoxin testing (USP <85>), donor screening verification, and viral marker clearance.
Chain-of-Custody and Temperature Tracking: Ensure the distributor uses validated cold-chain packaging (e.g., vapor-phase liquid nitrogen or dry ice shippers) with temperature indicators to maintain stability during transit.
Compliant Product Labeling and Literature: Review product inserts to confirm that marketing materials and indications for use adhere strictly to homologous structural applications without off-label drug claims.

Clinical vs. Operational Perspectives on Vendor Vetting

Integrating tissue products into a medical facility requires alignment between the clinical team and practice administrators. While both roles aim for patient wellness, their evaluation criteria differ markedly.

The Clinical Perspective

Physicians and medical directors focus on handling characteristics, structural integrity, sterility assurance, and clinical utility. Clinicians must ensure that the structural matrix provided matches the exact tissue repair demands of their surgical or outpatient procedures. They require transparent documentation showing that the processing method preserves tissue architecture without introducing cytotoxic residues or extraneous chemicals.

The Operational Perspective

Practice managers and administrators evaluate procurement mechanics, financial sustainability, liability mitigation, and workflow integration. Their concerns focus on:

Cost Efficiency and Margins: Assessing total cost per tissue unit, minimum order quantities, and delivery schedules to maintain efficient inventory levels.
Audit Readiness: Ensuring that all product inserts, donor tracking logs, and lot numbers can be logged into the electronic health record (EHR) system to satisfy external facility audits.
Risk Mitigation: Protecting the practice against regulatory enforcement actions resulting from unapproved Section 351 drug distributions mislabeled as Section 361 tissue products.

Distributors who maintain comprehensive regulatory dossiers streamline operational onboarding, allowing practice managers to present fully compliant vendor files to internal risk committees.

What This Means for Your Practice: Concrete Next Actions

To ensure your facility operates safely and efficiently while sourcing regenerative allografts, administrators should implement a standardized vendor compliance review:

Audit Current Biologics Inventory: Review all human tissue products currently stored in your clinical freezers or supply cabinets. Verify that each item includes a corresponding Lot CoA and donor tracking form.
Request Distributor Regulatory Packets: Contact existing vendors and request an updated compliance packet containing their FDA tissue establishment registration number, state distribution licenses, and sample CoAs.
Establish Standard Operating Procedures (SOPs): Create strict receiving SOPs requiring clinical staff to log incoming lot numbers, verify temperature indicators upon opening shippers, and file tissue intake forms prior to patient application.
Educate Clinical and Patient-Facing Staff: Ensure that marketing team members and clinical staff understand compliant language surrounding tissue allografts, avoiding non-homologous or disease-curing claims.
Review Vendor Accreditation Status: Verify whether suppliers collaborate with accredited tissue banks that maintain American Association of Tissue Banks (AATB) standards.

For further details on how regulatory standards intersect with clinical supply workflows, review our insights on practice compliance and sourcing in our FAQ section.

Partnering with Compliant Biologics Suppliers

Navigating tissue compliance requires a distributor that prioritizes regulatory transparency above all else. Dallas Regenerative Solutions operates as a licensed medical device and biologics distributor in the state of Texas, supplying verified tissue products and advanced devices exclusively to licensed healthcare providers and practices.

By enforcing rigid compliance protocols, chain-of-custody tracking, and comprehensive regulatory documentation, we help practices deliver high-quality patient care while safeguarding operational integrity. To discuss vendor onboarding, review product regulatory documentation, or explore compliant biologics for your facility, contact our team today.